eMERGE Network

eMERGE Network
Name	eMERGE Network
Formation	2007
Founder	National Institutes of Health; National Human Genome Research Institute
Type	Consortium
Location	United States
Focus	Genomics; Electronic Health Record integration; Return of Results

eMERGE Network is a multi-site consortium that integrates large-scale genomics with electronic health record (EHR) data to advance precision medicine. Established with support from the National Institutes of Health and the National Human Genome Research Institute, the Network brings together academic medical centers, biobanks, and informatics groups to perform genotype-phenotype discovery, implement genomic medicine in clinical settings, and study ethical, legal, and social implications. Its work interfaces with clinical laboratories, regulatory agencies, and population cohorts to inform implementation strategies across diverse populations.

History

The Network began in 2007 following funding by the National Institutes of Health and the National Human Genome Research Institute to demonstrate linkage of genotypic data to longitudinal electronic health record data. Early phases emphasized genome-wide association studies through collaborations including Vanderbilt University Medical Center, Group Health Cooperative, and Marshfield Clinic; later phases expanded to include clinical sequencing, pharmacogenomics, and clinical return-of-results pilots. Successive funding cycles involved collaborations with entities such as the Wellcome Trust, the US Food and Drug Administration, and the Centers for Disease Control and Prevention on policy-relevant projects. Milestones included integration with national initiatives like All of Us Research Program and methodological contributions to consortia such as the International HapMap Project and the 1000 Genomes Project through shared resources and standards.

Organization and Participating Institutions

The consortium links multiple academic centers, healthcare systems, and biorepositories including Vanderbilt University Medical Center, Massachusetts General Hospital, Geisinger Health System, Mayo Clinic, Columbia University Irving Medical Center, and Northwestern University. Governance has involved steering committees with representation from the National Human Genome Research Institute, institutional principal investigators, data coordinating centers, and bioethics teams from institutions such as Johns Hopkins University and University of Washington. Collaborations extend to clinical laboratories accredited by College of American Pathologists and regulatory stakeholders like the US Food and Drug Administration. Data sharing and informatics coordination have involved partnerships with the Database of Genotypes and Phenotypes, the Global Alliance for Genomics and Health, and the National Center for Biotechnology Information.

Research Objectives and Study Design

Primary objectives include discovery of genotype-phenotype associations, evaluation of genomic predictors for clinical outcomes, and implementation science for returning medically actionable findings. Study designs range from cross-sectional analyses of existing biobank-linked EHRs to prospective cohort studies and randomized implementation pilots. Phenotyping strategies leverage EHR-derived algorithms validated against manual chart review at centers such as Vanderbilt University Medical Center and Massachusetts General Hospital. Projects address diverse clinical domains including cardiology, oncology, pharmacogenomics, and rare disease, interfacing with initiatives like ClinicalTrials.gov for trial registration and coordination.

Genomic Data Collection and Bioinformatics

Genomic data collection has included genome-wide genotyping arrays, exome sequencing, and targeted gene panels performed in CLIA-certified laboratories including academic cores at Mayo Clinic and commercial partners. Bioinformatics pipelines harmonize variant calling, annotation, and imputation using resources such as the 1000 Genomes Project, gnomAD, and the Ensembl and RefSeq gene models. Data integration employs standardized vocabularies and ontologies derived from SNOMED CT, LOINC, and the Human Phenotype Ontology to enable cross-site analyses. Centralized data coordination leverages expertise from the Broad Institute and the University of Michigan for secure data repositories and phenotype harmonization.

Clinical Implementation and Return of Results

A central thrust has been pilots of clinical return of genomic results, including pathogenic variants in genes recommended by professional bodies like the American College of Medical Genetics and Genomics (ACMG). Implementation efforts developed workflows for clinical confirmation, genetic counseling, and EHR documentation at centers such as Geisinger Health System and Vanderbilt University Medical Center. Collaborations with payers and health technology assessment groups informed reimbursement and clinical utility assessments, alongside regulatory considerations involving the US Food and Drug Administration. Training and workforce development drew on curricula from institutions like Harvard Medical School and Stanford University School of Medicine.

Major Findings and Publications

The Network contributed to numerous high-impact publications characterizing genotype-phenotype associations, demonstrating feasibility of linking biobank genotypes to EHR phenotypes, and reporting outcomes of return-of-results pilots. Key outputs informed pharmacogenomic guidelines from organizations such as the Clinical Pharmacogenetics Implementation Consortium and variant interpretation frameworks promulgated by the American College of Medical Genetics and Genomics. Publications appeared in journals including Nature Genetics, The New England Journal of Medicine, and JAMA. Findings influenced carrier screening, population screening strategies, and development of risk prediction models evaluated against cohorts from Framingham Heart Study and UK Biobank.

Ethical, Legal, and Social Implications (ELSI)

ELSI research addressed informed consent models, participant preferences for return of results, privacy risks associated with genomic and EHR linkage, and equity in genomic research engagement across populations served by institutions such as Howard University and University of California, San Francisco. Workstreams engaged bioethicists from Georgetown University and legal scholars advising on issues intersecting with laws such as the Health Insurance Portability and Accountability Act and policy guidance from the National Academies of Sciences, Engineering, and Medicine. Community engagement strategies involved partnerships with advocacy groups including Genetic Alliance and disease-specific organizations such as the American Cancer Society.

Category:Genomics consortia